| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
Metabolite; ER; steroid hormone
|
|---|---|
| ln Vitro |
Ovariectomized mice had reduced levels of β-catenin and GSK-3β in their luminal and glandular epithelia after receiving treatment with estradiol dipropionate (2μg per 100 g; single subcutaneous injection) and chorionic gonadotropin (10 IU per 100 g; sc; twice a day) for two days[1].
The incidence of atypical endometrial hyperplasia is significantly higher, the level of β-catenin is slightly higher, and the expression of GSK-3β is lower in luminal and glandular epithelia after treatment with estradiol dipropionate (2 μg per 100 g; once a week) and chorionic gonadotropin (10 IU per 100 g; once a day) for a month[1]. |
| ln Vivo |
β-catenin and GSK in luminal and glandular epithelium following 2 days of treatment with estradiol dipropionate (2 μg/100 g; single subcutaneous injection) and chorionic gonadotropin (10 IU/100 g; subcutaneous injection; twice daily) Levels of -3β are lower in ovariectomized animals [1]. After one month of treatment with estradiol dipropionate (2μg/100g; once a week) and chorionic gonadotropin (10IU/100g; once a day), the incidence of atypical endometrial hyperplasia was dramatically raised, and the level of β-catenin rose. The expression of GSK-3β is slightly higher in high luminal epithelium and glandular epithelium, while the expression of GSK-3β is lower [1].
|
| Animal Protocol |
This work examined the effect of chorionic gonadotropin on proliferative and morphogenetic reactions in the uterus under short- and long-term estrogen treatments. Ovariectomized mice received a single injection with estradiol dipropionate (2 micro g per 100 g; subcutaneously, sc) or vehicle and injections with human chorionic gonadotropin (10 IU per 100 g; sc) or vehicle twice a day for 2 days. Other groups of animals received injections with estradiol once a week or vehicle and injections with chorionic gonadotropin or vehicle once a day for 30 days. The uteri were removed 48 h after the last estradiol or vehicle injection. In animals treated with estradiol and chorionic gonadotropin for a month, the incidence of atypical endometrial hyperplasia was significantly higher. In animals treated with estradiol and chorionic gonadotropin for 2 days or for a month, uterine mass was slightly increased, the number of mitotic cells and BrdU-labeled cells was greater in luminal epithelium, glandular epithelium, stromal and myometrial cells, whereas the expression of estrogen receptors-alpha was lower in all uterine compartments, than in control. In mice who received estradiol and chorionic gonadotropin for 2 days, levels of beta-catenin and glycogen synthase kinase-3beta in luminal and glandular epithelia were lower. In animals treated with estradiol and chorionic gonadotropin for a month, the level of beta-catenin was slightly higher, and the expression of glycogen synthase kinase-3beta was lower in luminal and glandular epithelia. Thus, chorionic gonadotropin exerts estradiol-induced proliferative and morphogenetic changes in the uterus. This action of chorionic gonadotropin is associated with decreased expression of estrogen receptors-alpha and with changes in expression of beta-catenin and glycogen synthase kinase-3beta in the uterus.[1]
|
| References | |
| Additional Infomation |
Estradiol dipropionate is a steroid ester.
Estradiol Dipropionate is the synthetic dipropionate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability. (NCI04) |
| Molecular Formula |
C24H32O4
|
|---|---|
| Molecular Weight |
384.52
|
| Exact Mass |
384.23
|
| Elemental Analysis |
C, 74.97; H, 8.39; O, 16.64
|
| CAS # |
113-38-2
|
| Related CAS # |
113-38-2; Alpha-Estradiol;57-91-0;Estradiol (Standard);50-28-2;Estradiol-d3;79037-37-9;Estradiol-d4;66789-03-5;Estradiol-d5;221093-45-4;Estradiol-13C2;82938-05-4;Estradiol (cypionate);313-06-4;Estradiol benzoate;50-50-0;Estradiol enanthate;4956-37-0;Estradiol hemihydrate;35380-71-3;Estradiol-d2;53866-33-4;Estradiol-13C6;Estradiol-d2-1;3188-46-3;rel-Estradiol-13C6; 979-32-8 (valerate); 113-38-2 (dipropionate); 57-63-6 (ethinyl); 172377-52-5 (sulfamate); 3571-53-7 (undecylate)
|
| PubChem CID |
8225
|
| Appearance |
White to off-white solid powder
|
| Density |
1.14g/cm3
|
| Boiling Point |
487.8ºC at 760mmHg
|
| Melting Point |
104-106℃ (ethanol )
|
| Flash Point |
238.5ºC
|
| Vapour Pressure |
3.58E-09mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
5.179
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
601
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O(C(C([H])([H])C([H])([H])[H])=O)[C@@]1([H])C([H])([H])C([H])([H])[C@@]2([H])[C@]3([H])C([H])([H])C([H])([H])C4C([H])=C(C([H])=C([H])C=4[C@@]3([H])C([H])([H])C([H])([H])[C@@]21C([H])([H])[H])OC(C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
JQIYNMYZKRGDFK-RUFWAXPRSA-N
|
| InChi Code |
InChI=1S/C24H32O4/c1-4-22(25)27-16-7-9-17-15(14-16)6-8-19-18(17)12-13-24(3)20(19)10-11-21(24)28-23(26)5-2/h7,9,14,18-21H,4-6,8,10-13H2,1-3H3/t18-,19-,20+,21+,24+/m1/s1
|
| Chemical Name |
[(8R,9S,13S,14S,17S)-13-methyl-3-propanoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] propanoate
|
| Synonyms |
Estradiol dipropionate; Estronex; Diprostron; Diovocylin; Agofollin; Progynon-DP; Dimenformon dipropionate; Diovocyclin; Follicyclin P; Estroici
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 21~62.5 mg/mL (54.6~162.5 mM)
Ethanol: ~20 mg/m L(~52.0 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6006 mL | 13.0032 mL | 26.0064 mL | |
| 5 mM | 0.5201 mL | 2.6006 mL | 5.2013 mL | |
| 10 mM | 0.2601 mL | 1.3003 mL | 2.6006 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA